PRESS RELEASES

DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).

Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at variant rs1967309 in the ADCY9 gene.

DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications.

DalCor Pharmaceuticals today announced the appointment of Dr. David G. Kallend as Chief Scientific Officer effective July 1, 2020.

DalCor Pharmaceuticals today announced the appointment of Diane E. Sullivan as Chief Commercial Officer effective June 1, 2020. Ms. Sullivan joins DalCor from The Medicines Company where she held the position of Chief Commercial Officer and has extensive leadership experience in both life sciences and technology at U.S. and U.K. based multi-national corporations.

DalCor Pharmaceuticals today announced that following the results of the interim futility analysis of the dalcetrapib dal-GenE Phase 3 trial, DalCor will continue the dal-GenE trial as recommended by the independent Data and Safety Monitoring Board (DSMB).

DalCor Pharmaceuticals today announced the appointment of Paul R. Fonteyne to Chairman of the Board effective February 27, 2019.

DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular  outcomes trial in coronary heart disease.

DalCor today announced the appointment of Peter Schuepbach as Vice President of Technical Operations.

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode as Chief Executive Officer, effective April 3, 2018. Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.

DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients.

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode to its Board of Directors. Dr. Laghrissi-Thode is VicePresident at AstraZeneca.

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dalGenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into this cardiovascular outcomes study of dalcetrapib.

DalCor Pharmaceuticals today announced that senior management will present at the Bloom Burton & Co.

DalCor Pharmaceuticals today announced that senior management will participate at the 16th Needham & Co. Healthcare Conference taking place April 4-5, 2017 at the Westin Grand Central in New York.

DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene.

DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will present data at the American Heart Association Scientific Sessions 2016 (AHA) during the Abstract Rapid Fire Session on Sunday, November 13, 2016 in New Orleans.

DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene.

DalCor Pharmaceuticals and The Montreal Heart Institute today announced the publication in Circulation Cardiovascular Genetics of data demonstrating dalcetrapib’s genotype-dependent effects on high-sensitivity C-reactive protein (hs-CRP) from the prospective analysis of a randomized, placebo controlled clinical trial that included 5243 genotyped patients with acute coronary syndrome (ACS).

DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. The worldwide clinical trial will be led by the Montreal Heart Institute.

DalCor Pharmaceuticals today announced the completion of $150 million in private financing to continue development of dalcetrapib in a genetically distinct population of patients with cardiovascular disease.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor), which will target patients with a specific genotype who have experienced a recent Acute Coronary Syndrome (ACS) event.

DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.